FDA Approves First PARP Inhibitor For Treatment Of Pancreatic Cancer
In December, the U.S. Food and Drug Administration (FDA) approved olaparib (Lynparza) for the maintenance treatment of adult patients with germline BRCA-mutated metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen, according to AstraZeneca and Merck. The agent is now the only PARP inhibitor approved for … Read more